2. Academic Validation
  3. Structure-activity relationship of N-methyl-N-aralkyl-peptidylamines as novel N-type calcium channel blockers

Structure-activity relationship of N-methyl-N-aralkyl-peptidylamines as novel N-type calcium channel blockers

  • Bioorg Med Chem Lett. 1999 Aug 2;9(15):2151-6. doi: 10.1016/s0960-894x(99)00359-5.
L Y Hu 1,  T R Ryder,  M F Rafferty,  D J Dooley,  J J Geer,  S M Lotarski,  G P Miljanich,  E Millerman,  D M Rock,  S J Stoehr,  B G Szoke,  C P Taylor,  M G Vartanian
Affiliations

Affiliation

  • 1 Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA.
PMID: 10465535 DOI: 10.1016/s0960-894x(99)00359-5
Abstract

Selective N-type voltage sensitive Calcium Channel (VSCC) blockers have shown efficacy in several animal models of stroke and pain. In the process of searching for small molecule N-type Calcium Channel blockers, we have identified a series of N-methyl-N-aralkyl-peptidylamines with potent functional activity at N-type VSCCs. The most active compound discovered in this series is PD 173212 (11, IC50 = 36 nM in the IMR-32 assays). SAR and pharmacological evaluation of this series are described.

Figures
Products